# Oleic acid content is responsible for the reduction in blood pressure induced by olive oil

S. Terés*, G. Barceló-Coblijn*, M. Benet*, R. Álvarez*, R. Bressani†, J. E. Halver‡§, and P. V. Escribá*§

*Laboratory of Molecular Cell Biomedicine, Department of Biology, Institut Universitari d'Investigacions en Ciències de la Salut, University of the Balearic Islands, Carretera de Valldemossa Km 7.5, E-07122 Palma de Mallorca, Spain; †Centro de Ciencia y Tecnología de Alimentos, Instituto de Investigación, University of Guatemala, Guatemala City, Guatemala; and ‡School of Aquatic and Fishery Sciences, University of Washington, Seattle, WA 98195

Contributed by J. E. Halver, August 1, 2008 (sent for review June 17, 2008)

**Numerous studies have shown that high olive oil intake reduces blood pressure (BP). These positive effects of olive oil have frequently been ascribed to its minor components, such as α-tocopherol, polyphenols, and other phenolic compounds that are not present in other oils. However, in this study we demonstrate that the hypotensive effect of olive oil is caused by its high oleic acid (OA) content (≈70–80%). We propose that olive oil intake increases OA levels in membranes, which regulates membrane lipid structure ($H_{II}$ phase propensity) in such a way as to control G protein-mediated signaling, causing a reduction in BP. This effect is in part caused by its regulatory action on G protein-associated cascades that regulate adenylyl cyclase and phospholipase C. In turn, the OA analogues, elaidic and stearic acids, had no hypotensive activity, indicating that the molecular mechanisms that link membrane lipid structure and BP regulation are very specific. Similarly, soybean oil (with low OA content) did not reduce BP. This study demonstrates that olive oil induces its hypotensive effects through the action of OA.**

aorta | fatty acids | membrane structure | signaling proteins | membrane-lipid therapy

Adrenergic receptors (α- and β-adrenoceptors) are key elements in the central and peripheral control of blood pressure (BP). Recent studies showed that the activity of the adrenoceptor signaling pathway can be regulated by oleic acid (OA) (*cis*-18:1n-9) (1), specifically because of the effect of this fatty acid on the structure of cell membranes (1, 2). However, similar modulation of G protein-coupled receptor signaling is not induced by structurally different but closely related fatty acids with identical or similar chemical composition, such as elaidic acid (*trans*-18:1n-9) or stearic acid (18:0). Nevertheless, a structural analogue of OA, 2-hydroxyoleic acid, can regulate membrane lipid structure and cell signaling in a similar manner as OA, evidence of the high structural specificity (3–5).

Mediterranean areas have a significantly lower incidence of cardiovascular heart disease when compared with other European countries. This phenomenon has been associated with dietary habits (6, 7), which improve parameters associated with major risk factors for cardiovascular disease, such as the lipoprotein profile (8, 9), BP (10), endothelial function (11), and inflammation and oxidative stress (12). Virgin olive oil (VOO) is one of the main components of the Mediterranean diet, and it contains high levels of monounsaturated fatty acids (MUFAs), mainly OA (70–80%) that is incorporated into triacylglycerides (TGs). Long-term intake of high doses of VOO reduces BP and the risk of developing hypertension (13–16). At the molecular level, OA and VOO regulate G protein-associated signaling both *in vivo* (in humans) and in cell culture (1, 17). Interestingly, the hypotensive effect of 2-hydroxyoleic acid involves changes in the same signaling pathways as those affected by OA (18, 19). However, some studies associate the cardioprotective activity of VOO with minor components characteristic of olive oil, such as α-tocopherol, polyphenols, and other phenolic compounds (16, 20–23). In this study, we demonstrate that the high OA content is responsible for the normotensive effects of olive oil consumption.




**Fig. 1.** Chronic effects of soybean oil, VOO, or TO treatments on systolic BP. Sprague–Dawley rats received vehicle (V), soybean oil (SO; 2 g·kg$^{-1}$), VOO (2 g·kg$^{-1}$), and TO (1 g·kg$^{-1}$), p.o. every 12 h for 14 days. Each value represents the mean ± SEM ($n$ = 10). *, $P < 0.05$ and **, $P < 0.01$ vs. vehicle-treated rats (ANOVA).

We have recently shown that OA, but not its structural analogues elaidic and stearic acid, regulates the activity of the $\alpha_{2A/D}$-adrenoreceptor/G protein/adenylyl cyclase-cAMP/PKA system by modulating the structure of plasma membrane lipids (1). Free or esterified, OA can modify the biophysical properties of membranes, specifically increasing the nonlamellar ($H_{II}$) phase propensity of the membrane (2, 3). In turn, this modification affects the docking of important membrane-associated signal transduction proteins involved in controlling BP, such as G proteins (1, 24, 25). In fact, altered levels and function of G proteins have been reported in both hypertensive humans (26, 27) and experimental models of hypertension (28, 29).

The present study was designed to investigate the molecular bases of the hypotensive effect of VOO. For this purpose, we compared the effects of VOO, triolein (TO; the main constituent of VOO, consisting of a TG with three OA moieties) and OA (the main fatty acid present in VOO) on BP. All of these treatments induced similar hypotensive effects in rats. In contrast, elaidic acid, stearic acid, and soybean oil (with low OA content) had little effect on BP.

## Results

**Effects of Soybean Oil, VOO, and TO on BP.** The effects of soybean oil, VOO, and TO treatments on BP were investigated in Sprague–Dawley rats. Chronic administration of VOO and TO

BIOCHEMISTRY

Author contributions: R.B., J.E.H., and P.V.E. designed research; S.T., G.B.-C., M.B., and R.Á. performed research; R.B., J.E.H., and P.V.E. analyzed data; and R.B., J.E.H., and P.V.E. wrote the paper.

The authors declare no conflict of interest.

§To whom correspondence may be addressed. E-mail: halver@u.washington.edu or pablo.escriba@uib.es.

© 2008 by The National Academy of Sciences of the USA




**Fig. 2.** Acute effects of VOO, TO, and OA on systolic BP. Sprague–Dawley rats received one p.o. dose of vehicle (V), VOO (2 g·kg$^{-1}$), TO (1 g·kg$^{-1}$), or OA (1 g·kg$^{-1}$). Systolic BP (expressed in mm Hg) was measured 2 h after administration (acute treatment). Each value represents mean ± SEM ($n$ = 10). *, $P < 0.05$ and ***, $P < 0.001$ vs. vehicle-treated rats (ANOVA).

over 14 days significantly reduced the BP in treated rats when compared with rats that received vehicle alone (26 ± 4.0 and 21 ± 3.4 mm Hg, respectively, $P < 0.001$; Fig. 1). Similarly, acute (2 h) exposure to both VOO and TO also reduced systolic BP (20 ± 0.3 mm Hg, $P < 0.001$, and 14 ± 1.7 mm Hg, $P < 0.05$, respectively; Fig. 2). Although diastolic BP changed in a similar manner to systolic BP, these reductions were not significant. In contrast, soybean oil, which contains little OA, did not induce a reduction in BP after chronic administration (Fig. 1). Furthermore, heart rate was not significantly affected by chronic or acute administration of these products when compared with vehicle-treated rats (Tables 1 and 2).

**Effects of OA, Elaidic Acid, and Stearic Acid on BP.** Whereas TGs constitute the major component of VOO, OA is the main metabolite of this oil in the body. Therefore, we studied the effect of this *cis*-MUFA on BP in rats. Like VOO and TO, chronic oral administration of OA induced a marked reduction in systolic BP in Sprague–Dawley rats (Fig. 3), which was 17 ± 1.9 mm Hg lower than in vehicle-treated rats after 14-day treatment (Fig. 3; $P < 0.05$). The hypotensive effect of OA was also observed after acute treatments, which reduced systolic BP by 13.0 ± 0.3 mm Hg (Fig. 2; $P < 0.001$). In contrast, treatment with the *trans*-MUFAs elaidic or stearic acid (saturated fatty acid) did not significantly affect BP (Fig. 3 and Table 2).

**Effects of VOO on BP in Spontaneously Hypertensive Rats (SHRs).** VOO (2 g·kg$^{-1}$) was also able to reduce the elevated BP in an animal model of hypertension (Fig. 4*A*), inducing a significant and progressive sustained reduction in systolic BP from as soon as 4 days after the onset of the treatment. Thus, there was a 26-mm Hg reduction ($P < 0.001$, Student's $t$ test) in the BP of SHRs after 14 days of treatment when compared with the animals that received the vehicle alone (Fig. 4*A*). Similarly, OA induced marked and significant reductions of BP in these hypertensive animals ($P < 0.001$), whereas stearic acid and elaidic acid did not significantly change the BP of SHRs (Fig. 4*B*).

**Table 1. Effects of chronic administration of soybean oil, VOO, and TO on diastolic BP and heart rate values in rats**

| BP/heart rate | Vehicle | Soybean oil | VOO | TO |
|---|---|---|---|---|
| Diastolic BP, mm Hg | 102.4 ± 3.1 | 108.6 ± 6.8 | 94.0 ± 2.0 | 100.2 ± 2.7 |
| Heart rate, beats per min | 356 ± 9 | 376 ± 5 | 354 ± 3 | 377 ± 14 |

Sprague–Dawley rats received vehicle, soybean oil (2 g·kg$^{-1}$), VOO (2 g·kg$^{-1}$), and TO (1 g·kg$^{-1}$) p.o. every 12 h for 14 days. Diastolic BP and heart rate values were measured as described in *Materials and Methods*. Each value represents the mean ± SEM ($n$ = 10).

**Table 2. Effect of acute VOO, TO, and OA administration on diastolic BP and heart rate values in rats**

| BP/heart rate | Vehicle | VOO | TO | OA |
|---|---|---|---|---|
| Diastolic BP, mm Hg | 99.4 ± 3.6 | 91.0 ± 2.6 | 97.1 ± 3.1 | 91.4 ± 4.6 |
| Heart rate, beats per min | 348 ± 9 | 347 ± 1 | 341 ± 8 | 327 ± 8 |

Sprague–Dawley rats received a single dose (p.o.) of vehicle, VOO (2 g·kg$^{-1}$), TO (1 g·kg$^{-1}$) ,and OA (1 g·kg$^{-1}$). Diastolic BP and heart rate values were measured as described in *Materials and Methods*. Each value represents the mean ± SEM ($n$ = 10).

**Effects of VOO, TO, and OA on Signaling Proteins in the Aorta.** Because OA regulates G protein-mediated signaling in 3T3 cells *in vitro* (1), we investigated whether this molecular mechanism was also involved in the *in vivo* activity of OA, TO, and VOO. Hence, we measured the levels of important signaling proteins involved in the control of BP in the aorta. The concentrations of G proteins and phospholipase C $\beta$1 (PLC$\beta$1$\alpha$/$\beta$) were determined by quantitative immunoblotting in aorta tissue from Sprague–Dawley rats treated with OA, TO, VOO, or the vehicle alone for 14 days. After treatment with these lipids, there was a down-regulaton of the aortic G proteins that inhibit adenylyl cyclase (AC), G$\alpha i_2$ (Fig. 5*A*) and G$\alpha i_3$ (Fig. 5*B*), when compared with vehicle-treated rats (note that G$\alpha i_1$ is not expressed in rat aorta) (30). When compared with vehicle-treated rats, the overall levels of G$\alpha i_2$ and G$\alpha i_3$ proteins in the aorta fell by 28% and 34% after OA administration, by 40% and 28% after exposure to TO, and by 34% and 34% after VOO treatment (Fig. 5 *A* and *B*). Similarly, the amounts of aortic G$\alpha$q/11 decreased significantly by 26%, 35%, and 31% after OA, TO, and VOO treatments, respectively (Fig. 5*C*). Thus, we investigated whether proteins downstream G$\alpha$q/11 might also be affected by the administration of these lipids. Like G$\alpha$q/11, chronic OA, TO, and VOO induced significant decreases in the total PLC$\beta$1 levels in the aorta (52%, 33%, and 24%, respectively; Fig. 5*D*).

**Effects of VOO and Soybean Oil on Membrane Structure.** We have studied the effects of OA and TGs on model membrane structure, specifically on the lamellar-to-hexagonal (L-to-$H_{II}$) transition temperature of 1,2-eladyl phosphatidylethanolamine




**Fig. 3.** Chronic effects of OA, elaidic acid and stearic acid on systolic BP. Sprague–Dawley rats received vehicle (V), OA (1 g·kg$^{-1}$), elaidic acid (EA; 1 g·kg$^{-1}$), or stearic acid (SA; 1 g·kg$^{-1}$) p.o. every 12 h for 14 days. Each value represents the mean ± SEM ($n$ = 10). *, $P < 0.05$ vs. vehicle-treated rats (ANOVA).

**Table 3. Effect of chronic administration of OA, elaidic acid, and stearic acid on diastolic BP and heart rate values in rats**

| BP/heart rate | Vehicle | OA | Elaidic acid | Stearic acid |
|---|---|---|---|---|
| Diastolic BP, mm Hg | 102.4 ± 3.1 | 96.2 ± 1.7 | 106.4 ± 6.5 | 109.6 ± 0.9 |
| Heart rate, beats per min | 358 ± 9 | 388 ± 13 | 348 ± 13 | 378 ± 1 |

Sprague–Dawley rats received vehicle, OA (1 g·kg$^{-1}$), elaidic acid (1 g·kg$^{-1}$), and stearic acid (1 g·kg$^{-1}$) p.o. every 12 h for 14 days. Diastolic BP and heart rate values were measured as described in *Materials and Methods*. Each value represents the mean ± SEM ($n$ = 10).

(DEPE) by differential scanning calorimetry (2–4). We assessed the effect of VOO and soybean oil on membrane lipid structure, and we found that, in agreement with the effect exerted by their major TGs constituents, both oils induced marked reductions in the L-to-$H_{II}$ phase transition (3). The outcome of these measurements was compared with results obtained for a series of structurally and chemically related fatty acids and TO (Fig. 6) (3, 4). We found that there was a tendency for the reduction induced by these lipids on BP to be correlated with the *in vitro* effect on the L-to-$H_{II}$ phase transition ($r = 0.67$; $P = 0.07$; $n = 8$) (Fig. 6*A*). The failure to identify a significant relationship was mainly caused by the anomalous behavior of soybean oil, which did not reduce BP to the same extent as it regulated the membrane structure. However, the digestion by lipases of both olive and soybean oils results in the release of free fatty acids. Therefore, the differences in the hypotensive effects of olive and soybean oil were most likely caused by their different OA content. In agreement with this hypothesis, the correlation between the reduction in BP and the dose of *cis*-MUFAs administered to animals was highly significant ($r = 0.94$; $P < 0.001$; $n = 8$; Fig. 6*B*). Moreover, we also found significant correlation between the dose of *cis*-MUFA fatty acids received and the *in vitro* effect on the L-to-$H_{II}$ phase transition ($r = 0.83$; $P < 0.01$; $n = 8$; result not shown).




**Fig. 4.** Effects of VOO treatment on BP in SHRs. (*A*) Rats received vehicle or VOO (2 g·kg$^{-1}$) p.o. every 12 h for 14 days. Time course of systolic BP (expressed in mm Hg) in vehicle-treated SHRs (Control) and VOO-treated SHRs (olive oil). (*B*) Chronic (14-day) effects of vehicle (Control), OA, stearic acid (SA), and elaidic acid (EA) on systolic BP of SHR. *, $P < 0.05$; **, $P < 0.01$; and ***, $P < 0.001$ versus vehicle-treated SHRs (Student's *t* test in *A* and ANOVA in *B*).

## Discussion

The interest in the potential cardiovascular health benefits of VOO has increased since Mediterranean diets with high olive oil intake were shown to improve the serum lipoprotein profile (HDL-to-LDL ratio) and reduce BP, insulin resistance, and systemic markers of inflammation in cardiovascular-risk patients (14, 16, 31, 32). Most of these studies have involved months of VOO intake or other oils (13, 16), on the hypothesis that metabolic molecular mechanisms are associated with long adaptive cellular and physiologic processes. However, we demonstrated here that short (2 h and 2 wk) treatments can also lower systolic BP, through a mechanism of action based on the rapid regulation of membrane lipid structure and cell signaling (2–4 h) and rather quick (3–4 days) adaptive processes.

**OA Is Responsible for the Hypotensive Effects of Olive Oil.** In a study of a human population with controlled diets, which only varied in the type of oil used, VOO induced marked and significant reductions in BP with respect to sunflower seed oil (17). Numerous studies suggest that this and other beneficial effects of VOO on cardiovascular health are caused by minor components present in this oil (23). However, we demonstrate here that OA is responsible for the hypotensive effects of olive oil. In this context, VOO induced marked and significant reductions of BP after both acute (2 h) and chronic, yet short (2 wk), administration, unlike soybean oil. Although the hypotensive effects of acute (single dose) olive oil were transient (with a peak at 2–4 h after treatment), reductions in BP were not only marked but they were also stable after 3 or 4 days of high olive oil intake. This rather rapid effect after acute intake of free fatty acids and related lipids is most likely caused by their easy transfer from the small intestine to blood vessels, where they can regulate cell signaling in vascular cells. VOO is composed of TGs, mainly TO (with three OA moieties), which comprises >50% of all TGs in VOO, followed in abundance by TGs with two OA moieties. Indeed, TO itself also induced marked and significant reductions in BP, although it is unlikely that TGs alone are responsible for the hypotensive effects of olive oil. Indeed, these lipids are the substrates of lipases that readily digest TGs to release the free fatty acid moieties and hence, cells receive mainly the processed lipids. Furthermore, although soybean oil has a high TGs content it has little OA and it was unable to reduce BP in rats. Finally, the MUFA OA (the main component in both VOO and TO) also induced a marked and significant decrease in systolic BP, and the dose of MUFA administered to animals was closely correlated with the reduction in BP. Accordingly, it appears that the major fatty acid found in olive oil, OA, would account for the hypotensive effects of this nutrient.

By contrast, elaidic acid (*trans* 18:1n-9 isomer of OA) and stearic acid (18:0) do not induce significant changes in BP despite their chemical similarity with OA, which would argue against the involvement of other metabolic factors. It indicates that the fatty acid structure is critical to produce hypotension. Moreover, elaidic and stearic acids appeared to be ineffective to lower BP in SHRs, whereas both OA and VOO exerted normontensive (hypotensive) effects in these hypertensive animals, further

BIOCHEMISTRY




**Fig. 5.** Effects of VOO, TO, and OA treatments on total G protein $\alpha i_2$, $\alpha i_3$ and $\alpha_{q/11}$ subunits and PKC$\beta$1 levels in aorta. Sprague–Dawley rats received vehicle (V), VOO (2 g·kg$^{-1}$), TO (1 g·kg$^{-1}$), or OA (1 g·kg$^{-1}$) p.o. every 12 h for 14 days. Insets show representative immunoblots of aortic G protein $\alpha_{i2}$ (*A*), G protein subunit $\alpha_{i3}$ (*B*), G protein subunit $\alpha_{q/11}$ subunit (*C*), and PLC$\beta$1 (PLC$\beta$1a + PLC$\beta$1b) (*D*) after vehicle, VOO, TO, or OA administration. The amount of total protein loaded was 24 $\mu$g for G$\alpha_{i2}$, $\alpha_{i3}$, and $\alpha_{q/11}$ subunits and 80 $\mu$g for PLC$\beta$1. The columns represent the mean ± SEM (*n* = 5) of total protein levels quantified against standard curves and normalized to the protein content from vehicle-treated rats (taken as 100%). *, $P < 0.05$ and **, $P < 0.01$ vs. vehicle-treated rats (ANOVA).

supporting the beneficial action of high-OA-containing diets on human health (Fig. 4).

**Molecular Mechanisms Involved in the Hypotensive Effects of Olive Oil.** The intensive intake of VOO increases the *cis*-MUFA levels in cell membranes (16, 17), which augments the nonlamellar-phase propensity of the membranes (2, 3). By contrast, trans-MUFA and saturated fatty acids do not significantly change the membrane curvature strain. The "molecular shape" of lipids (33) in part explains their different effects on membrane structure and cell physiology. The presence of the nonlamellar-prone lipid, OA, in the lipid bilayer induces a decrease in the surface packing of phospholipid headgroups (34, 35). In turn, this favours the docking of certain peripheral signaling proteins involved in the control of BP (e.g., G proteins and PKC) (5, 25). In this scenario, bulky isoprenyl moieties, such as those found through the posttranslational modification of the G$\gamma$ subunits of trimeric G proteins, can be inserted into membrane microdomains with a loose surface packing (i.e., high nonlamellar-phase propensity), whereas they are excluded from microdomains with tight packing such as lipid rafts. G protein heterotrimers prefer $H_{II}$-prone regions, whereas G$\alpha$i monomers prefer lamellar-prone structures (e.g., lipid rafts) where myristic and palmitic acids (saturated fatty acids) can be readily inserted (25). These preferences may account for the reduction in G$\alpha$ proteins observed in membranes of animals that have a high OA intake. Thus, membrane microdomains with different lipid structures probably act as cell signaling platforms with specific and divergent functions.

Unlike its analogues, elaidic and stearic acid, OA regulates membrane lipid structure in 3T3-cells and the $\alpha_2$-adrenergic receptor system involved in the control of BP ($\alpha_{2A/D}$-adrenoreceptor/G protein/adenylyl cyclase-cAMP/PKA) (1). Moreover, we have shown that this signaling pathway can also be regulated *in vivo*, because the structural analogue of OA (2-hydroxyoleic acid) reduces BP. Indeed, this hypotensive effect can be reversed in rats by administration of the PKA blocker Rp-8-BrcAMP, which affects the last protein in this canonical signaling cassette (19). Together, these results indicate a direct relationship between the composition and structure of lipid membranes and BP regulation, which is supported by the relationships we have shown here. In addition, the results provide a rational bases for the positive (in the case of *cis*-MUFA) or negative effects (in the case of *trans*-MUFA and saturated fatty acids) that diets enriched in different lipids might have on cardiovascular health.

It was previously shown that human hypertensive subjects have altered levels of membrane lipids and G proteins (27), and that long-term olive oil intake reduces the membrane concentrations of G proteins (17). In the present study, we observed a similar effect in rats treated with VOO, TO, and OA, indicating that the adaptive mechanism is ultimately triggered by OA. All of these lipids induced reductions in the levels of G$\alpha i_2$, G$\alpha i_3$, G$\alpha_{q/11}$, and PLC$\beta$. Moreover, this down-regulation of vascular smooth muscle of vasoconstrictory proteins, G$\alpha_{q/11}$ and PLC$\beta$, is associated with a decrease in the levels of the second messengers, inositol phosphate, diacylglycerol, and $Ca^{2+}$ (36). Interestingly, OA inhibits inositol-(1, 4, 5)-triphosphate and diacylglycerol production, with a concomitant blockage of $Ca^{2+}$-mediated cell signaling (37). These second messengers are produced from phosphatidylinositol by PLC$\beta$, and their reduced concentration in cells would be in agreement with a decrease in the levels of the enzyme, as shown in this work. Similarly, rats treated with OA, TO, and VOO express significantly less inhibitory G$\alpha$i proteins ($Gi_2$ and $Gi_3$) in the aorta. The net result is an enhancement of the vasodilator pathway $\alpha_2$-adrenoreceptor/G protein/adenylyl




**Fig. 6.** Correlations between BP reductions (mmHg) and decrease of L-to-$H_{II}$ phase transition temperature (°C; *A*) or the dose of *cis*-MUFA (g/kg) administered to animals (*B*). Each numbered point represents the treatment: treatment 1, VOO; treatment 2, 2-hydroxyoleic acid; treatment 3, TO; treatment 4; OA; treatment 5, stearic acid; treatment 6; vehicle; treatment 7, elaidic acid; treatment 8, soybean oil. Solid lines represent the regression of the correlations, whose correlation coefficients (*r*) and statistical significance (*P*) are shown in both cases.

cyclase-cAMP/PKA that provokes a lowering of the BP and limits the effects of other vasoconstriction pathways (18, 19). Accordingly, deficient AC activity in vascular cells, caused by altered G protein levels and function, diminishes intracellular cAMP levels, a hallmark of hypertension in humans (38, 39) and in experimental animal models (30). Indeed, a rise in the expression of inhibitory $G_i$ proteins in the aorta of hypertensive animals precedes the development of high BP, which is probably a major contributory factor in the pathogenesis of hypertension (29, 30, 40, 41). In addition, 2-hydroxyoleic acid regulates transient outward $K^+$ current in cardiomyocytes, which might be associated with the cardioprotective effects of *cis*-MUFA (42). Furthermore, these studies all support a relationship between lipid structure, cell signaling, and BP.

**Concluding Remarks: Membrane-Lipid Structure in the Regulation of BP.** High intake of the nonlamellar prone fatty acid, OA (and structurally related analogues or precursors, such as 2-hydroxyoleic acid, VOO, and TO), increases the concentration of *cis*-MUFA in membranes. This concentration regulates the localization, activity, and expression of important signaling molecules in the adrenergic receptor pathway, enhancing the production of vasodilatory stimuli (e.g., cAMP and PKA) and restricting vasoconstriction pathways (inositol-triphosphate, $Ca^{2+}$, diacylglycerol, and Rho kinase) (19).

Like TGs, soybean oil increases the *in vitro* $H_{II}$ propensity in model membranes and thus, it could *a priori* have hypotensive properties. However, oils are readily degraded by lipases, so that the amounts of OA received by cells are insufficient to produce a hypotensive effect. For this reason the correlation between the reduction of BP and L-to-$H_{II}$ phase transition temperature was not significant. If the effect of soybean oil is disregarded, we can indeed demonstrate a statistically significant correlation between BP and the L-to-$H_{II}$ phase transition temperature ($r = 0.89$; $P < 0.01$; data not shown). Moreover, the correlation between the reduction of BP and the dose of *cis*-MUFA administered (considering also soybean oil) was also highly significant ($r = 0.94$; $P < 0.001$; $n = 8$), strongly supporting the hypothesis presented.

Thus, the present work partially unravels the molecular mechanisms involved in the beneficial effects of olive oil in the control of BP and the molecular basis of its favorable effects on human health. Although other minor component of VOO could also have some positive action on cardiovascular health, we have demonstrated that the beneficial effects of OA-enriched diets can be explained by the principles of "membrane-lipid therapy" (43). These principles would not only apply to *cis*-MUFA but also to the beneficial effects of $\omega$-3 fatty acids and the detrimental action of excessive intake of saturated and transunsaturated fats.

## Materials and Methods

**Animals, Treatments, and BP Measurements.** Female Sprague–Dawley rats or SHRs weighing 230–250 g (Charles River Laboratories) were kept at a constant temperature (24 ± 1°C) with a 12-h dark/light cycle. All rats were fed during the experiments with chow A04 purchased from Panlab, which contains 0.04% palmitic acid, 0.13% palmitoleic acid, 0.65% OA, 1.39% linoleic acid, and 0.13% linolenic acid. Animals were randomly divided into seven groups ($n = 10$ animals per group), and they received per oral (p.o.) administration every 12 h for 14 days of soybean oil (2 g·kg$^{-1}$; R.P. Sol Natural), VOO (2 g·kg$^{-1}$; Batlle Hermanos), TO (1 g·kg$^{-1}$), OA (1 g·kg$^{-1}$), elaidic acid (1 g·kg$^{-1}$), stearic acid (1 g·kg$^{-1}$; Sigma), or vehicle (water). In another series of experiments, male SHRs (250–300 g; Charles River Laboratories) were treated with VOO (2 g·kg$^{-1}$) or vehicle, and BP was measured before treatment (day 0, basal values) and on days 4, 6, 8, 11 and 14 of the treatments. In a different series of experiments, SHRs were treated with OA, stearic acid, elaidic acid (1 g·kg$^{-1}$), or vehicle (control), and BP was measured before treatment (basal BP) and at the end of 14-day treatments. We always used 10 SHRs per group.

Sprague–Dowley rats were used because they constitute a valuable model with little variability, appropriate to study the regulatory effects of fatty acids on BP (18). On the other hand, SHR is a well known model of hypertension (19), used in the present work to determine whether VOO might be useful to control high BP in human hypertensive subjects. The animals' body weight, BP, and heart rate were measured 2 h after each administration. BP and heart rate were measured by using a tail-cuff device connected to a computerized oscillometer (Nyprem system 645; Cibertec). This noninvasive method allows repeated measurements throughout the treatment period (44). In one series of experiments, Sprague–Dawley rats received a single p.o. administration of compound at the doses indicated above (acute treatments), and BP and heart rate were measured 2 h after administration. After the final measurement, the rats were killed by decapitation, and their aortas were dissected out and immediately frozen in liquid nitrogen before being stored at −80°C. All experiments were carried out in accordance with the guidelines laid down by the European Union and the Institutional Committee for Animal Research.

**Preparation of Aortic Homogenates.** Frozen aortas were ground in a glass mortar by using liquid nitrogen. The resulting powder was homogenized (1:10, wt/vol) by using a tissue blender (Ultra-Turrax; Janke & Kunkel) in ice-cold 10 mmol/liter Tris·HCl buffer, pH 7.5, containing 1 mmol/liter EDTA, 1% SDS, 1 mmol/liter PMSF, and 5 mmol/liter iodoacetamide. The homogenate was incubated for 30 min at room temperature and then submitted to ultrasound in a Branson Sonifier (W/450D) for 10 s at 50 W. Samples were then centrifuged for 15 min at 1,000 × *g* and 4°C, and 30-$\mu$l aliquots were removed from the resulting supernatant to assess the total protein present. The remaining supernatant was mixed with electrophoresis loading buffer [120 mmol/liter Tris·HCl (pH 6.8), 4% SDS, 50% glycerol, 0.1% bromophenol blue, and 10% $\beta$-mercaptoethanol], boiled for 5 min, and used for immunoblotting experiments.

**Immunoblots and the Quantification of Membrane-Associated Signaling Proteins.** Quantitative immunoblotting of G proteins ($G\alpha i_2$, $G\alpha i_3$, and $G\alpha q$/11) and PLC$\beta$1 in aorta homogenates from Sprague–Dawley rats was performed after

BIOCHEMISTRY

chronic treatments as described (18). The polyclonal antisera against G$\alpha$i$_3$ and G$\alpha$q/11 were obtained from Santa Cruz Biotecnology and that against G$\alpha$i$_2$ was from PerkinElmer, and the anti-PLC$\beta$1 antiserum was from BD Biosciences/Transduction Laboratories. Quantification of the immunoblots was performed by image analysis, using standard curves with four points of different protein content loaded on the same gels (i.e., total protein loaded vs. integrated optical density) as described (45). The quantification procedure was repeated at least three times for each sample on different gels. Values were normalized to the protein content of vehicle-treated rats (control, 100%).

**Differential Scanning Calorimetry.** Differential scanning calorimetry was performed on an MCS-DSC microcalorimeter (OriginLab) at a scan rate of 0.5 K/min as described (46). In brief, DEPE (5 mM) was dissolved in chloroform in the presence or absence of different concentrations of soybean oil and olive oil in a proportion of 20:1 (DEPE/oil, mole/mole assuming that the oils had the molecular weight of TO). The solvent was removed under an argon flux and then vacuum-dried for at least 3 h. Lipid films were subsequently resuspended in 10 mM Hepes buffer, pH 7.4, containing 100 mM NaCl, and 1 mM EDTA, by vortex shaking for 2 min at 50°C. These suspensions were degassed by stirring under vacuum for 10 min and immediately used in calorimetry experiments.

**Data Analysis.** The data are the mean $\pm$ SEM from the number of animals indicated. The statistical significance was calculated by using GraphPad software. One-way ANOVA followed by a Bonferroni's test or two-tailed *t* test (where indicated) was used for statistical evaluations. Differences were considered statistically significant at $P < 0.05$.

**ACKNOWLEDGMENTS.** This work was supported by Ministerio de Educación y Ciencia Grants SAF2003-00232, SAF2004-05249, and BFU2007-61071, Grants PROGECIC-3C and PCTIB2005GC4-07 from the Conselleria d'Economia, Hisenda i Innovació, Govern Balear, and the Marathon Foundation. S.T. holds a ''Torres-Quevedo'' contract and G.B.-C. holds a ''Juan de la Cierva'' contract.

1. Yang Q, *et al.* (2005) Influence of the membrane lipid structure on signal processing via G protein-coupled receptors. *Mol Pharmacol* 68:210–217.
2. Funari SS, Barceló F, Escribá PV (2003) Effects of oleic acid and its congeners, elaidic and stearic acids, on the structural properties of phosphatidylethanolamine membranes. *J Lipid Res* 44:567–575.
3. Prades J, Funari SS, Escribá PV, Barceló, F (2003) Effects of unsaturated fatty acids and triacylglycerols on phosphatidylethanolamine membrane structure. *J Lipid Res* 44:1720–1727.
4. Barceló, F, *et al.* (2004) The hypotensive drug 2-hydroxyoleic acid modifies the structural properties of model membranes. *Mol Membr Biol* 21:261–268.
5. Martínez J, *et al.* (2005) Membrane structure modulation, protein kinase C $\alpha$ activation, and anticancer activity of minerval. *Mol Pharmacol* 67:531–540.
6. Menotti A, *et al.* (1990) Twenty-five-year mortality from coronary heart disease and its prediction in five cohorts of middle-aged men in Finland, The Netherlands, and Italy. *Prev Med* 19:270–278.
7. Martínez-González MA, Sánchez-Villegas A (2004) The emerging role of Mediterranean diets in cardiovascular epidemiology: Monounsaturated fats, olive oil, red wine, or the whole pattern? *Eur J Epidemiol* 19:9–13.
8. Zambon D, *et al.* (2000) Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women: A randomized cross-over trial. *Ann Intern Med* 132:538–546.
9. Bemelmans WJ, *et al.* (2002) Effect of an increased intake of $\alpha$-linolenic acid and group nutritional education on cardiovascular risk factors: The Mediterranean $\alpha$-Linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. *Am J Clin Nutr* 75:221–227.
10. Psaltopoulou T, *et al.* (2004) Olive oil, the Mediterranean diet, and arterial blood pressure: The Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Am J Clin Nutr* 80:1012–1018.
11. Fuentes F, *et al.* (2001) Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. *Ann Intern Med* 134:1115–1119.
12. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C (2004) Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. *J Am Coll Cardiol* 44:152–158.
13. Alonso A, Martínez-González MA (2004) Olive oil consumption and reduced incidence of hypertension: The SUN study. *Lipids* 39:1233–1238.
14. Estruch R, *et al.* (2006) Effects of a Mediterranean-style diet on cardiovascular risk factors: A randomized trial. *Ann Intern Med* 145:1–11.
15. Perona JS, *et al.* (2007) Consumption of virgin olive oil influences membrane lipid composition and regulates intracellular signaling in elderly adults with type 2 diabetes mellitus. *J Gerontol A Biol Sci Med Sci* 62:256–263.
16. Ruiz-Gutiérrez V, Muriana FJ, Guerrero A, Cert AM, Villar J (1996) Plasma lipids, erythrocyte membrane lipids, and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources. *J Hypertens* 14:1483–1490.
17. Alemany R, *et al.* (2007) G protein-coupled receptor systems and their lipid environment in health disorders during aging. *Biochim Biophys Acta* 1768:964–975.
18. Alemany R, *et al.* (2004) 2-Hydroxyoleic acid: A new hypotensive molecule. *Hypertension* 43:249–254.
19. Alemany R, *et al.* (2006) Antihypertensive action of 2-hydroxyoleic acid in SHRs via modulation of the protein kinase A pathway and Rho kinase. *J Lipid Res* 47:1762–1770.
20. Visioli F, Galli C (2001) Antiatherogenic components of olive oil. *Curr Atheroscler Rep* 3:64–67.
21. Beauchamp GK, *et al.* (2005) Phytochemistry: Ibuprofen-like activity in extra-virgin olive oil. *Nature* 437:45–46.
22. Ferrara LA, *et al.* (2000) Olive oil and reduced need for antihypertensive medications. *Arch Intern Med* 160:837–842.
23. Rodriguez-Rodriguez R, Herrera MD, de Sotomayor MA, Ruiz-Gutiérrez V (2007) Pomace olive oil improves endothelial function in spontaneously hypertensive rats by increasing endothelial nitric oxide synthase expression. *Am J Hypertens* 20:728–734.
24. Escribá, PV, Wedegaertner PB, Goñi FM, Vögler O (2007) Lipid–protein interactions in GPCR-associated signaling. *Biochim Biophys Acta* 1768:836–852.
25. Vögler O, *et al.* (2004) The G$\beta\gamma$ dimer drives the interaction of heterotrimeric Gi proteins with nonlamellar membrane structures. *J Biol Chem* 279:36540–36545.
26. Feldman RD, Chorazyczewski J (1997) G-protein function is reduced in hypertension. *Hypertension* 29:422–427.
27. Escribá, PV, Sánchez-Domínguez JM, Alemany R, Perona JS, Ruiz-Gutiérrez V (2003) Alteration of lipids, G proteins, and PKC in cell membranes of elderly hypertensives. *Hypertension* 41:176–182.
28. Clark CJ, Milligan G, McLellan AR, Connell JM (1992) Guanine nucleotide regulatory protein levels and function in spontaneously hypertensive rat vascular smooth-muscle cells. *Biochim Biophys Acta* 1136:290–296.
29. Marcil J, de Champlain J, Anand-Srivastava MB (1998) Overexpression of Gi-proteins precedes the development of DOCA-salt-induced hypertension: Relationship with adenylyl cyclase. *Cardiovasc Res* 39:492–505.
30. Anand-Srivastava, MB (1992) Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition. *Biochem J* 288:79–85.
31. Heyden S, Kluthe R, Immenhofer C (1994) International symposium on sodium and hypertension: Results of randomized trials. *Clin Invest* 72:800–803.
32. Mata P, *et al.* (1992) Effect of dietary monounsaturated fatty acids on plasma lipoproteins and apolipoproteins in women. *Am J Clin Nutr* 56:77–83.
33. Israelachvili JN, Marcelja S, Horn RG (1980) Physical principles of membrane organization. *Q Rev Biophys* 13:121–200.
34. Lehtonen JY, Holopainen JM, Kinnunen PK (1996) Evidence for the formation of microdomains in liquid crystalline large unilamellar vesicles caused by hydrophobic mismatch of the constituent phospholipids. *Biophys J* 70:1753–1760.
35. Kinnunen PKJ (1996) On the molecular level mechanisms of peripheral protein–membrane interactions induced by lipids forming inverted nonlamellar phases. *Chem Phys Lipids* 81:151–166.
36. Pérez FR, Piñeiro V, De La Cruz LF, Casanueva FF, Casabiell X (2003) Vascular wall: potential target for the physicochemical effects of *cis*-unsaturated free fatty acids. *Microsc Res Tech* 60:23–29.
37. Casabiell, X, Pandiella A, Casanueva, FF (1991) Regulation of epidermal-growth-factor-receptor signal transduction by cis-unsaturated fatty acids: Evidence for a protein kinase C-independent mechanism. *Biochem J* 278:679–687.
38. Werstiuk ES, Lee RM (2000) Vascular $\beta$-adrenoceptor function in hypertension and in aging. *Can J Physiol Pharmacol* 78:433–452.
39. Webb JG, Yates PW, Yang Q, Mukhin YV, Lanier SM (2001) Adenylyl cyclase isoforms and signal integration in models of vascular smooth muscle cells. *Am J Physiol* 281:H1545–H1552.
40. Di Fusco F, Anand-Srivastava MB (2000) Enhanced expression of Gi proteins in nonhypertrophic hearts from rats with hypertension-induced by L-NAME treatment. *J Hypertens* 18:1081–1090.
41. Li Y, Anand-Srivastava MB (2002) Inactivation of enhanced expression of G(i) proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats. *Circ Res* 91:247–254.
42. Borchert GH, *et al.* (2008) 2-Hydroxyoleic acid affects cardiomyocyte [$Ca^{2+}$]i transient and contractility in a region-dependent manner. *Am J Physiol* 294:H1948–H1955.
43. Escribá, PV (2006) Membrane-lipid therapy: A new approach in molecular medicine. *Trends Mol Med* 12:34–43.
44. Pfeffer JM, Pfeffer MA, Frohlich ED (1971) Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. *J Lab Clin Med* 78:957–962.
45. Escribá, PV, Sastre M, García-Sevilla JA (1994) Increased density of guanine nucleotide-binding proteins in the postmortem brains of heroin addicts. *Arch Gen Psychiatry* 51:494–501.
46. Escribá PV, Morales P, Smith A (2002) Membrane phospholipid reorganization differentially regulates metallothionein and heme oxygenase by heme-hemopexin. *DNA Cell Biol* 21:355–364.